90 results
8-K
EX-99.1
APRE
Aprea Therapeutics Inc
10 Apr 24
IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented
4:15pm
) is to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of single-agent APR-1051 in advanced solid tumors harboring … the Recommended Phase 2 Dose (RP2D)
The primary objectives are to measure safety, dose-limiting toxicities (DLTs), maximum tolerated dose or maximum
8-K
EX-99.2
APRE
Aprea Therapeutics Inc
10 Apr 24
IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented
4:15pm
significant unmet medical need, are synergistic with other anticancer therapies, and potentially differentiated in safety and tolerability ATR - Ataxia … -clinical proof-of-principle Anti-tumor activity at nanomolar concentration Preserved hematologic safety profile Best in class, next generation Pre-clinical
8-K
EX-99.1
APRE
Aprea Therapeutics Inc
26 Mar 24
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
8:15am
Tumors, APR-1051) trial. This dose escalation trial will evaluate the safety, tolerability, and preliminary efficacy of APR-1051. Enrollment
8-K
EX-99.2
APRE
Aprea Therapeutics Inc
26 Mar 24
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
8:15am
significant unmet medical need, are synergistic with other anticancer therapies, and potentially differentiated in safety and tolerability ATR - Ataxia … -clinical proof-of-principle Anti-tumor activity at nanomolar concentration Preserved hematologic safety profile Best in class, next generation Pre-clinical
8-K
EX-10.1
m9ak2nl6yfvr4gsjsl0y
12 Mar 24
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
4:31pm
8-K
EX-99.2
ewc2zvb4s3
12 Mar 24
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
4:31pm
8-K
EX-99.1
jpmdl erg
6 Feb 24
Other Events
5:01pm
8-K
EX-99.1
72xf415npd
4 Jan 24
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
4:16pm
8-K
EX-99.2
nwyo3
4 Jan 24
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
4:16pm
8-K
EX-99.1
yh2u6wp
9 Nov 23
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:15pm
8-K
EX-99.2
hoefo5fcfvdku4yh
9 Nov 23
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:15pm
8-K
EX-99.1
awb1konrbhc1k
13 Oct 23
Other Events
7:31am
8-K
EX-99.1
zq94zswry
11 Sep 23
Other Events
8:30am
8-K
EX-99.2
ofrp52x4nyrri
10 Aug 23
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
7:36am
8-K
EX-99.1
p2o6h 16kjg
10 Aug 23
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
7:36am